<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2557">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03175874</url>
  </required_header>
  <id_info>
    <org_study_id>17-PP-03</org_study_id>
    <nct_id>NCT03175874</nct_id>
  </id_info>
  <brief_title>Autophagy and Pathological Aging</brief_title>
  <acronym>AVP</acronym>
  <official_title>AVP Study: Autophagy and Pathological Aging Human Study in Osteoporosis With or Without Dementia of Alzheimer's Type</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Autophagy is recognized as a central mechanism for the regulation of aging. . Osteoporosis&#xD;
      (OA) and Alzheimer's disease (AD) are two forms of pathological aging, sometimes entangled,&#xD;
      including an over-risk of OP in AD and degradation of cognitive functions after OP fracture,&#xD;
      but the link between These two pathologies remain poorly understood.&#xD;
&#xD;
      The aim of this prospective pilot study is to evaluate the level of autophagy of osteocytes&#xD;
      (OST) in postmenopausal women with OP and to explore the hypothesis that the defect of&#xD;
      autophagy is one of the physiopathological links of the OP During the MA&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Autophagy is a ubiquitous cellular mechanism that degrades and recycles toxic waste from&#xD;
      cells. It is recognized as a central mechanism for the regulation of aging. Osteoporosis (OA)&#xD;
      and Alzheimer's disease (AD) are two forms of pathological aging, sometimes entangled,&#xD;
      including an over-risk of OP in AD and degradation of cognitive functions after OP fracture,&#xD;
      but the link between These two pathologies remain poorly understood. In Alzheimer's disease&#xD;
      (AD), a deficiency of autophagy is found both clinically and fundamentally. In animal&#xD;
      studies, animal studies have shown that autophagy is involved in the differentiation,&#xD;
      function and survival of bone cells, decreases with age and that a defect in autophagy is&#xD;
      accompanied by a decrease in The bone mass. To date, we do not have human data on the&#xD;
      autophagic capacities of bone cells in OP and AD.&#xD;
&#xD;
      The aim of this prospective pilot study is to evaluate the level of autophagy of osteocytes&#xD;
      (OST) in postmenopausal women with OP and to investigate the hypothesis that the defect of&#xD;
      autophagy is one of the physiopathological links of the OP During the MA.&#xD;
&#xD;
      The main objective is to determine, in two subgroups with or without Alzheimer's disease,&#xD;
      whether there is an association between bone status and the level of autophagy of OST in&#xD;
      postmenopausal women (OP versus non-OP)&#xD;
&#xD;
      Secondary objectives are to determine whether there is an association between the level of&#xD;
      autophagy of the OST and the bone parameters (bone mineral density, serum vitamin D) and to&#xD;
      compare in OP women the level of autophagy of the OST Of AM patients vs no MA.&#xD;
&#xD;
      Study population: Postmenopausal women over the age of 65 benefiting from the implantation of&#xD;
      a hip prosthesis: 30 with an OP fracture of the femoral neck (15 non-MA and 15 MA, the&#xD;
      cognitive status being determined by MMSE And IADL 1 month after the fracture) and 30&#xD;
      controls performed for osteoarthritis, free from OP (antecedents + bone mineral density) and&#xD;
      MA (MMSE and IADL).&#xD;
&#xD;
      Primary endpoint: Quantification of autophagy (LC3II and SQSTM1 / p62) by Western blotting of&#xD;
      purified OST proteins from a bone sample from resected femoral heads during laying of a total&#xD;
      prosthesis Of hip.&#xD;
&#xD;
      Secondary endpoints: Bone mineral density of femoral neck and total hip (T-score and g / cm²)&#xD;
      measured by X-ray biphotonic absorptiometry (Hologic QDR 4500) and serum 25 OH vitamin D (ng&#xD;
      / ml).&#xD;
&#xD;
      Expected benefits: to better understand the role of autophagy in the pathophysiology of&#xD;
      post-menopausal OP and AD in human pathology. Ultimately, it could potentially contribute to&#xD;
      the design of new therapeutics targeting autophagy in the management of osteoporosis and more&#xD;
      generally pathological aging.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">December 20, 2017</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Quantification of autophagy (LC3II and SQSTM1 / p62) by Western blotting of purified OST proteins from a bone sample from resected femoral heads during laying of a total hip prosthesis.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quantification of autophagy</measure>
    <time_frame>at inclusion</time_frame>
    <description>Quantification of autophagy (LC3II and SQSTM1 / p62) by Western blotting of purified OST proteins from a bone sample from resected femoral heads</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bone mineral density</measure>
    <time_frame>at inclusion</time_frame>
    <description>Bone mineral density of femoral neck and total hip (T-score and g / cm²) as measured by X-ray biphotonic absorptiometry (Hologic QDR 4500)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>25 OH vitamin D (ng/ml).</measure>
    <time_frame>at inclusion</time_frame>
    <description>25 OH vitamin D (ng/ml) in serum</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>osteoporosis and alzheimer</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patient with osteoporosis and alzheimer hospitalized for total hip prosthesis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>osteoporosis without alzheimer</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patient with osteoporosis without alzheimer hospitalized for total hip prosthesis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient with arthrosis without alzheimer</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patient with arthrosis without alzheimer hospitalized for total hip prosthesis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hip bone sampling</intervention_name>
    <description>Quantification of autophagy (LC3II and SQSTM1 / p62) by Western blotting of purified OST proteins from a bone sample</description>
    <arm_group_label>Patient with arthrosis without alzheimer</arm_group_label>
    <arm_group_label>osteoporosis and alzheimer</arm_group_label>
    <arm_group_label>osteoporosis without alzheimer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Inclusion criteria for both groups:&#xD;
&#xD;
          -  Women &gt; 65 y: 2 groups&#xD;
&#xD;
        Inclusion criteria for Osteoporosis group (Alzheimer and non-Alzheimer):&#xD;
&#xD;
          -  Osteoporotic femoral neck fracture requiring hip remplacement and fullfilling WHO&#xD;
             definition of osteoporosis. Without any cognitive impairment for the first subgroup&#xD;
             (MMSE &gt; 26 and normal IADL) and with a final diagnosis of alzheimer disease in the&#xD;
             other subgroup (DSM-IV-TR)&#xD;
&#xD;
        Inclusion criteria for Control group:&#xD;
&#xD;
          -  Non osteoporotic (no fragility fracture (clinical or on VFA) and bone mineral density&#xD;
             T-score &gt; 2.5 SD at all sites)&#xD;
&#xD;
          -  No cognitive impairment (MMSE &gt; 26 and normal IADL)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Non-Inclusion Criteria for both groups:&#xD;
&#xD;
          -  Other pathologies associated with autophagy: Parkinson's disease, Crohn's disease,&#xD;
             cancers, myopathies, type 2 diabetes&#xD;
&#xD;
          -  Méd Medications interfering with autophagy: current corticosteroids, parathyroid&#xD;
             hormone, estrogen, chloroquine, hydroxychloroquine, lithium, metformin,&#xD;
             bisphosphonates,&#xD;
&#xD;
          -  Dementia of non-Alzheimer type&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Veronique BREUIL, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Nice</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Veronique BREUIL, PhD</last_name>
    <phone>0492035512</phone>
    <email>breuil.v@chu-nice.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>BREUIL</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>VERONIQUE BREUIL, MD</last_name>
      <phone>4 92 03 55 12</phone>
      <phone_ext>+33</phone_ext>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>May 29, 2017</study_first_submitted>
  <study_first_submitted_qc>June 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2017</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoporosis</keyword>
  <keyword>Alzheimer Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

